Home  >  News
Eppen_Multichannel_Jul24
you can get e-magazine links on WhatsApp. Click here
Technology + Font Resize -

Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

Paris, New York
Wednesday, May 22, 2024, 13:00 Hrs  [IST]

Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the pharma and life sciences industries.

Sanofi will leverage this partnership to provide access to proprietary data to develop AI models as it continues on its path to becoming the first biopharma company powered by AI at scale.

Paul Hudson, CEO, Sanofi, said: “This unique collaboration is the next significant step in our journey to becoming a pharmaceutical company substantially powered by AI. Next generation, first-of-its kind AI model customizations will be an important foundation in our efforts to shape the future of drug development for pharma and for the many patients waiting for innovative treatments.”

OpenAI, the world leader in AI technology, will contribute access to cutting-edge AI capabilities, including the ability to fine-tune models, deep AI expertise and dedicated thought partnership and resources.

Brad Lightcap, COO, OpenAI, said: “There is massive potential for AI to accelerate drug development. We are excited to collaborate with Sanofi and Formation Bio to help patients and their families by bringing new medicines to market.”

Formation Bio, an AI and tech-driven drug developer with its own pipeline of drug assets, will provide extensive engineering resources, experience operating at the intersection of pharma and AI, and its tech-driven development platform to design, develop and deploy AI technologies across all aspects of the pharma lifecycle.

Benjamine Liu, co-founder & CEO, Formation Bio, said: “I firmly believe that by combining our strengths, Sanofi, OpenAI and Formation Bio can reimagine drug development in the pharma industry. By creating and implementing customized AI agents and models designed for our industry, companies like Sanofi and Formation Bio can begin to scale with unprecedented productivity and transform the pace at which we bring new medicines to patients.”

The potential positive impact of AI for patients waiting for new treatments is tremendous and Sanofi, Formation Bio and OpenAI plan to lead the way for drug developers.

Formation Bio is a tech-driven and AI-native pharma differentiated by radically more efficient drug development. Advancements in AI and drug discovery are creating more candidate drugs than the industry can progress because of the high cost and time of clinical trials.

OpenAI is an AI research and deployment company. Its mission is to ensure that artificial general intelligence benefits all of humanity.

Sanofi is an innovative global healthcare company, driven by one purpose: it chase the miracles of science to improve people’s lives.

 




*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
avians24_PB
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram